What are the adverse effects of CJC-1295, ipamorelin and tesamorelin together?

The short answer

CJC-1295 and ipamorelin raise growth hormone and IGF-1, and most of their side effects follow directly from that: water retention (puffy hands, tingling or numbness), head-rush or flushing right after injection, injection-site reactions, vivid dreams or sleep changes, joint aches, and — with sustained use — higher blood sugar. Ipamorelin is relatively selective, so it causes less cortisol and prolactin rise than older GHRPs. Most effects are dose-related and ease at lower doses.

Evidence tier: Tier 1–2 for the GH/IGF-1-driven effects; Tier 3 (anecdotal) for some commonly-reported ones like dry eyes. Educational content, not medical advice.

The key points:

• Most side effects are the GH effect — fluid retention drives many of them
• Ipamorelin is selective — less cortisol/prolactin than hexarelin or GHRP-6
• Blood sugar can rise with sustained GH/IGF-1 elevation
• Nearly all are dose-related — lower dose and slower titration usually fix them

For the stack itself, see the CJC-1295 / ipamorelin guide.

Why these two are stacked (and why that shapes side effects)

Evidence tier: 2 — established pharmacology.

CJC-1295 is a GHRH analog and ipamorelin is a GHRP (ghrelin-receptor agonist) — two different signals to the pituitary that combine for a bigger growth-hormone pulse than either alone. CJC-1295 comes in two forms that matter a lot for side effects: the DAC version, engineered for a long half-life that keeps GH/IGF-1 elevated for days (Teichman et al. 2006), and the no-DAC/"mod GRF" version, which is short-acting and produces a sharper, more pulsatile release. Sustained elevation (DAC) tends to bring more of the fluid-retention-type effects; pulsatile dosing tends to be gentler.

Ipamorelin's selling point is selectivity: unlike older growth-hormone-releasing peptides such as GHRP-6 or hexarelin, it stimulates GH with comparatively little rise in cortisol and prolactin, and less of the intense hunger GHRP-6 is known for. That's genuinely relevant to the side-effect profile — many of the classic GHRP complaints (big appetite spikes, cortisol-related effects) are milder here. What ipamorelin doesn't escape is the downstream consequence of raising GH and IGF-1 itself, which is where most of the real side effects come from.

What are the common side effects?

Evidence tier: 1–2 — consistent with GH-secretagogue class data.

Fluid retention is the headline, and it explains several complaints at once. Raising GH makes the kidneys hold sodium and water, so people get puffy hands or face, swollen ankles, a few pounds of "water weight," and — importantly — numbness or tingling in the hands when the swelling compresses the nerve at the wrist (covered in depth in GH peptides: numb hands & fluid retention). Joint aches and a general "full/stiff" feeling often come from the same fluid shift (GH-secretagogue safety review).

The other frequent ones: a head rush, warmth, or facial flushing in the minutes after injection (a recognized GHRP effect, usually brief); injection-site reactions — redness, itching, small lumps (see injection-site reactions); sleep changes, most often unusually vivid dreams or deeper sleep, since GH secretagogues interact with sleep architecture; lightheadedness if you dose and stand up quickly; and fatigue or lethargy in some users, particularly at higher doses. Appetite can increase, though noticeably less than with GHRP-6.

What about dry eyes, and the less-documented complaints?

Evidence tier: 3 — anecdotal, mechanistically plausible.

Dry or gritty-feeling eyes come up repeatedly in community reports on CJC-1295 (especially no-DAC) and ipamorelin, and it's worth being straight about the evidence: this isn't well documented in the clinical literature. There's no trial establishing dry eye as a recognized side effect of these peptides. That said, it's mechanistically plausible — GH/IGF-1 elevation shifts fluid balance throughout the body, and the tear film is sensitive to fluid and hormonal changes, so a fluid-mediated effect on eye comfort isn't far-fetched. It also tends to be reported alongside other fluid-retention symptoms, which fits that explanation.

The honest framing: treat dry eyes as a plausible but unconfirmed effect. Practically, if it appears alongside puffiness and tingling, it's likely part of the same fluid picture and should ease with a lower dose. If it's severe, persistent, or the only symptom, don't just attribute it to the peptide — dry eye has many causes (screens, antihistamines, thyroid, autoimmune conditions) and deserves an actual eye exam. The same logic applies to other commonly-reported-but-unstudied complaints: take them seriously as your experience, respond by adjusting dose, but don't assume the peptide is the cause without ruling out the ordinary explanations.

What if you're running tesamorelin as well?

This is the most common version of the question we see, and it is worth separating out, because adding tesamorelin to CJC-1295 and ipamorelin is not simply "a third compound".

CJC-1295 and tesamorelin do the same job. Both are GHRH analogues — modified versions of growth-hormone-releasing hormone that act on the same pituitary receptor. Ipamorelin is a different mechanism (a ghrelin-receptor agonist, or GHRP), which is why GHRH + GHRP is the classic pairing. Running tesamorelin and CJC-1295 means two drugs pushing the same receptor. You are not adding a mechanism; you are adding dose, cost and side-effect exposure to a pathway you were already stimulating.

That has a direct consequence for side effects: the effects of this stack are the growth-hormone axis's effects, and they are shared rather than separate. Fluid retention, carpal-tunnel-type numbness and tingling, joint and knuckle pain, and effects on glucose handling are all GH-axis phenomena. Two GHRH analogues do not produce two different side-effect profiles — they produce more of the same one.

In our own post corpus, the overlap is visible in what people report:

Numbness and tingling and fluid retention appear on both lists. Those are the two to watch, and they are covered in detail in GH peptides, fluid retention and carpal tunnel — the single most common reason people stop this class.

One of these three is not like the others. Tesamorelin is FDA-approved as Egrifta, which means it has real trial data behind it — but approved specifically for excess visceral fat in people with HIV-associated lipodystrophy. That approval tells you the drug has been studied; it does not transfer to using it alongside two unapproved compounds for body composition in a healthy adult. CJC-1295 and ipamorelin have no such approval anywhere. See Tesamorelin (Egrifta) and off-label use.

What we cannot tell you. There are no human studies of this three-compound combination. No interaction data exists for it, no dosing guidance derived from it, and no safety profile specific to it. What is written above is mechanism — two GHRH analogues act on one receptor — plus what posters report for the individual compounds. It is not an interaction study, because there isn't one.

If you are stacking all three and seeing hand swelling, numbness, or night-time wrist pain, that is the predictable GH-axis effect of the combination, it is dose-related, and it generally resolves on reducing or stopping. If it does not, that is a conversation with a clinician rather than a forum.

Which side effects actually matter?

Evidence tier: 1–2 — metabolic and long-term concerns.

Most of the above is nuisance-level. Two things deserve more weight. First, blood sugar and insulin sensitivity: chronically elevated GH/IGF-1 tends to raise fasting glucose and reduce insulin sensitivity, a consistent finding across GH-secretagogue research — including the two-year trial of an oral secretagogue in older adults, which documented worsened insulin sensitivity alongside its lean-mass gains (Nass et al. 2008). That matters most for anyone with prediabetes, diabetes, metabolic-syndrome risk, or long-term continuous use, and it's the main reason to monitor rather than assume these peptides are metabolically neutral.

Second, IGF-1 elevation itself. Raising IGF-1 is the point of the stack, but IGF-1 is a growth signal, so sustained elevation is a more loaded decision for anyone with a personal or family cancer history or significant risk factors — a concern that scales with age (see peptides for seniors). This isn't evidence these peptides cause cancer; it's that the theoretical concern is real enough to warrant a clinician's input rather than indefinite self-directed use. Sensible monitoring for anyone using them seriously: IGF-1, fasting glucose, and blood pressure.

How do you reduce the side effects?

Evidence tier: 2 — practical, mechanism-based.

Nearly everything here is dose-related, which is the good news. The most effective lever is simply using less: lower the dose, or back off to the last dose you tolerated well, and most of the fluid-retention symptoms (puffiness, tingling, joint aches, possibly dry eyes) ease within days to weeks. Titrate up slowly rather than jumping to a high dose. If you're on CJC-1295 with DAC and struggling with fluid effects, the sustained elevation is a likely contributor — the shorter-acting no-DAC form produces a more pulsatile pattern that many tolerate better. Timing helps too: dosing before bed suits the sleep effects and the post-injection flush.

Also worth doing: rotate injection sites to limit local reactions, give the head-rush a minute (sit down after dosing if you get lightheaded), and monitor labs rather than guessing — IGF-1 and fasting glucose tell you whether you're pushing the system too hard. And know when to stop rather than adjust: numbness that's severe, constant, or involves hand weakness needs medical attention rather than dose-tinkering, as does any significant swelling with breathlessness. For how to switch or take breaks, see GH peptide cycling, washout and switching.

Limitations

This is educational content, not medical advice.

• Most side effects stem from GH/IGF-1 elevation — especially fluid retention — and are dose-related.
• Dry eyes and some reported effects are anecdotal, not established in the literature; rule out ordinary causes.
• Blood sugar and insulin sensitivity can worsen with sustained use — monitor, especially with metabolic risk.
• Sustained IGF-1 elevation warrants caution with cancer history or risk factors.
• Severe or persistent numbness/weakness needs medical attention, not just a dose change.
• Marko Maal, MSc Pharmacy reviewed this article. Reviewer attribution does not constitute a doctor-patient relationship.

The bottom line

Most CJC-1295 and ipamorelin side effects trace back to one thing: the growth hormone they're designed to raise. Fluid retention drives the puffy hands, tingling or numbness, joint aches, and water weight; the post-injection head rush and flushing are classic GHRP effects; vivid dreams, injection-site reactions, and lightheadedness are common; and ipamorelin's selectivity means less cortisol, prolactin, and hunger than older GHRPs. Dry eyes are frequently reported but unstudied — plausible via fluid shifts, worth an eye exam if severe. The effects that genuinely matter are the metabolic ones: rising blood sugar and falling insulin sensitivity with sustained use, plus the IGF-1 question for anyone with cancer risk. Nearly everything improves at a lower dose, so treat side effects as a signal you're above your ceiling — and monitor IGF-1 and glucose rather than assuming these are neutral.

Related on this site

• GH secretagogue cycling and desensitization
• Switching & cycling GH peptides: washout and breaks
• Are peptides safe for older adults?
• CJC-1295 / ipamorelin stack guide
• GH peptides: numb hands, swelling & fluid retention
• Switching & cycling GH peptides: washout & breaks
• GH peptides for muscle: the honest evidence
• Peptide injection-site reactions
• Our evidence-tier framework

References

• Teichman SL, et al. 2006. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295. J Clin Endocrinol Metab 91(3):799–805. PMID 16352683 — sustained vs pulsatile GH elevation.
• Sigalos JT, Pastuszak AW. 2018. The safety and efficacy of growth hormone secretagogues. Sex Med Rev. PMID 28400207 — class side-effect profile including fluid retention.
• Nass R, et al. 2008. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults. Ann Intern Med. PMID 18981485 — worsened insulin sensitivity with sustained GH-secretagogue use.